Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 671
- Registration Number
- NCT00219128
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1125
- Registration Number
- NCT00219154
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
- Conditions
- Asthma
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 133
- Registration Number
- NCT00219323
- Locations
- 🇯🇵
This study is not being conducted in the United States, Tokyo, Japan
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
- Conditions
- Treatment of Bone Metastases
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00219258
- Locations
- 🇨🇳
Beijing, Beijing, China
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
- Conditions
- Hypertension, Diabetes Mellitus
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 839
- Registration Number
- NCT00219089
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 844
- Registration Number
- NCT00219063
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 641
- Registration Number
- NCT00219193
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novartis
- Registration Number
- NCT00219219
- Locations
- 🇮🇹
Bologna, Bologna, Italy
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
- Conditions
- OsteoarthritisRheumatoid Arthritis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 135
- Registration Number
- NCT00170872
A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1422
- Registration Number
- NCT00171366
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States